Caris Life Sciences CAI
NASDAQ CAI
$25.09 -0.23 (-0.91%)
As of: Sep 4, 2026 · 3:59 PM EDT

Caris Life Sciences (CAI) Assets Average (2025 - 2026)

Caris Life Sciences (CAI) posted quarterly Assets Average of $1.1 billion for Q1 2026, up 8.43% quarter-over-quarter from $1.1 billion in Q4 2025.

Analysis

Caris Life Sciences (CAI) Assets Average (2025 - 2026) Analysis & Trends

Caris Life Sciences' Assets Average history runs 2 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

  • In Q1 2026, Assets Average changed N/A year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (changed N/A YoY), while the FY2025 annual figure was $734.7 million, changed N/A from the prior year.
  • Assets Average for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
  • The five-year high for Assets Average was $1.1 billion in Q1 2026, with the low at $969.8 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 26.95 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 11.22 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 3.29 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 8.86 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.34 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.09 Bn
10 Caris Life Sciences 7.08 Bn 6.28 Bn 182.38 Mn 1.20 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.20 Bn
Mar 31, 2026 1.14 Bn
Dec 31, 2025 1.06 Bn
Sep 30, 2025 969.81 Mn